Malin shareholders in line for windfall after €119 million cash boost
Dublin-based biotech investment fund said €45 million of the proceeds from the sale will be used to repay a European Investment Bank loan, with the remaining cash to be returned to shareholders later this year
Malin, the Dublin-based biotech investment fund, said it will return capital to shareholders in the second half of this year following the sale of its stake in a drug company for up to €119 million.
Kymab, a Cambridge-based company developing treatments for the immune system, is being acquired by drug giant Sanofi in a deal worth up to $1.45 billion. Malin owns about 10 per cent of Kymab and will receive $112 million (€92 million)...
Subscribe from just €1 for the first month!
What's Included
With any subscription you will have access to
-
Unlimited multi-device access to our iPad, iPhone and Android Apps
-
Unlimited access to our eReader library
-
Exclusive daily insight and opinion seven days a week
-
Create alerts to never miss a subject that matters to you
-
Get access to exclusive offers for subscribers on gifts and experiences
-
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Related Stories
‘I always had entrepreneurial ambitions and this was first-hand evidence of an unmet need’
Neuromod’s chief executive Dr Ross O’Neill says his company’s Lenire device, which aids tinnitus sufferers, can establish a sizeable market — particularly in the US among military veterans
PM Group reports 30% profits increase and announces 200 new jobs in Ireland
The project delivery firm said that pharmaceutical projects accounted for almost two-thirds of its overall revenue for 2020, which rose to almost €400 million
Neuromod Devices to double Irish headcount within next year
The medtech company, which specialises in neuromodulation devices indicated for the treatment of tinnitus, said it hopes to roll out its product in European countries such as France, Spain and the Netherlands
Chanelle founder invests €100k in Redesdale Group
Michael Burke has taken a stake in a firm that will seek to acquire or invest in early stage food and wellness businesses
